1. Restoration of t cell substes of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells: An in vitro study.
- Author
-
Montanucci, Pia, Alunno, Alessia, Basta, Giuseppe, Bistoni, Onelia, Pescara, Teresa, Caterbi, Sara, Pennoni, Ilaria, Bini, Vittorio, Gerli, Roberto, and Calafiore, Riccardo
- Subjects
- *
UMBILICAL cord , *MESENCHYMAL stem cells , *T cells , *TYPE 1 diabetes , *IN vitro studies - Abstract
Human umbilical cord Wharton jelly-derived mesenchymal stem cells (hUCMS) might apply to treating chronic autoimmune disorders, as already shown for Sjögren's syndrome, including type 1 diabetes mellitus (T1D). Since naked hUCMS grafts encountered restraints, we enveloped hUCMS, within immunoisolatory microcapsules (CpS-hUCMS), made of our endotoxin-free, clinical grade alginate. We then examined the vitro effects of interferon (IFN)-γ-pretreated CpS-hUCMS on Th17 and Treg of T1D patients (n = 15) and healthy controls (n = 10). Peripheral blood mononuclear cells (PBMCs) were co-cultured with PBMC/CpS-hUCMS: lymphocyte proliferation was assessed by carboxyfluorescein succinimidyl esther (CFSE) dilution assay, and phenotypic analysis of regulatory and effector Tc was also performed. Cytokine expression was performed by bead array and qPCR on IFN-γ-pretreated hUCMS before PBMCs co-culture. CpS-hUCMS restored a correct Treg/Th17 ratio, relevant to the T1D disease process. In summary, we have preliminarily developed a new biohybrid system, associated with immunoregulatory properties, that is ready for in vivo application. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF